This article has been cited by
1PMTDS: a computational method based on genetic interaction networks for Precision Medicine Target-Drug Selection in cancer
Varshini Vasudevaraja,Jamie Renbarger,Ridhhi Girish Shah,Garrett Kinnebrew,Murray Korc,Limei Wang,Yang Huo,Enze Liu,Lang Li,Lijun Cheng
Quantitative Biology.2017;5(4)380
2It is not appropriate to dismiss inappropriate care
Joseph E Ibrahim
Medical Journal of Australia.2015;203(4)161
3Regulatory innovation for expansion of indications and pediatric drug development
Min Soo Park
Translational and Clinical Pharmacology.2018;26(4)155
4Les Prescriptions médicamenteuses hors AMM (Autorisation de Mise sur le Marché) en France. Une clarification est indispensable
Gilles Bouvenot,Yves Juillet,Alain Saint-Pierre,Marie-Paule Serre
Bulletin de l'Académie Nationale de Médecine.2018;202(8-9)1749
5Off-label use of orphan medicinal products: a Belgian qualitative study
Marc Dooms,David Cassiman,Steven Simoens
Orphanet Journal of Rare Diseases.2016;11(1)1749
6The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
Marta Herrero Fernandez,Raquel Molina Villaverde,Monica Arroyo Yustos,Fatima Navarro Expósito,Jose Luis Lopez Gonzalez,Maria Rosario Luque Infantes,Melchor Alvarez-Mon Soto
Frontiers in Pharmacology.2019;10(1)1749
7Off-label use of medicines: The need for good practice guidelines
Marc Dooms,James Killick
International Journal of Risk & Safety in Medicine.2017;29(1-2)17
8Off-label Medications Use in the Eastern Province of Saudi Arabia: The Views of General Practitioners, Pediatricians, and Other Specialists
Zainab AbuAlsaud,Dhfer Alshayban,Royes Joseph,Faheem Hyder Pottoo,Jisha Myalil Lucca
Hospital Pharmacy.2018;29(1-2)001857871881786
9Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Aaron S. Kesselheim,Carolyn L. Treasure,Steven Joffe
PLOS Medicine.2017;14(1)e1002190
10Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Giuseppe Tridente
PLOS Medicine.2017;14(1)695
11Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
Guangrong Lu,Mayank Rao,Ping Zhu,Buqing Liang,Rasheda T. El-Nazer,Ekokobe Fonkem,Meenakshi B. Bhattacharjee,Jay-Jiguang Zhu
Frontiers in Neurology.2019;10(1)695
12Cognitive Effects of Perioperative Pregabalin
Marianne Myhre,Henrik Børsting Jacobsen,Stein Andersson,Audun Stubhaug
13Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases
Anne Loesche,Jana Wiese,Sven Sommerwerk,Vivienne Simon,Wolfgang Brandt,René Csuk
European Journal of Medicinal Chemistry.2017;125(3)430
14Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies
Katlein França,Sergio Litewka
International Journal of Dermatology.2019;58(7)788
15Repurposing Drugs in Oncology: Next Steps
Ciska Verbaanderd,Lydie Meheus,Isabelle Huys,Pan Pantziarka
Trends in Cancer.2017;3(8)543
16Drotaverine - a Concealed Cytostatic!
Ioana Z. Pavel,Lucie Heller,Sven Sommerwerk,Anne Loesche,Ahmed Al-Harrasi,René Csuk
Archiv der Pharmazie.2017;350(1)e1600289
17Drug repositioning, a new alternative in infectious diseases
Marissa Bolson Serafin,Rosmari Hörner
The Brazilian Journal of Infectious Diseases.2018;22(3)252
18From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries
Paola Minghetti,Elena P. Lanati,Josie Godfrey,Oriol Solà-Morales,Olivier Wong,Sonia Selletti
Medicine Access @ Point of Care.2017;1(3)maapoc.0000016
19Identifying Off-Label Prescriptions Through Data Mining in Danish Community Pharmacy Servers: An Exploratory Study on Desmopressin, Diclofenac, Fucidin, Mirtazapine and Quetiapine
Monika Andrulyte,Ole Jannik Bjerrum
Basic & Clinical Pharmacology & Toxicology.2018;123(2)155
20Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey
Federica Edith Pisa,Giorgia Cosano,Manuela Giangreco,Tullio Giorgini,Emanuele Biasutti,Fabio Barbone
Brain Injury.2015;29(4)508
21After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
Tim K. Mackey,Bryan A. Liang
Mayo Clinic Proceedings.2016;91(6)701
22Extended infusion—putting the benefit into context
Markus Zeitlinger
The Lancet Infectious Diseases.2018;18(4)380
23Trichotillomania (hair pulling disorder): Clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations
Katlein França,Anagha Kumar,David Castillo,Mohammad Jafferany,Marcelo Hyczy da Costa Neto,Katerina Damevska,Uwe Wollina,Torello Lotti
Dermatologic Therapy.2019;32(4)e12622
24Knowledge and attitudes of patients in primary care on off-label treatment
Mario Curkovic,Dražen Gorjanski
International Journal of Risk & Safety in Medicine.2018;29(3-4)181